Q2 Earnings Estimate for McKesson Issued By Leerink Partnrs

Key Points

• Analysts from Leerink Partners have revised their Q2 2026 earnings per share (EPS) estimate for McKesson to $8.32, down from $8.41, while the consensus estimate for the full year is $32.77 per share.
• McKesson's quarterly earnings reported on August 6 were $8.26 per share, missing the consensus estimate by $0.07, despite achieving revenues of $97.83 billion, which exceeded expectations.
• The company declared a quarterly dividend of $0.82 per share, an increase from the previous dividend of $0.71, reflecting a strong commitment to returning value to shareholders.

McKesson Corporation (NYSE:MCK - Free Report) - Analysts at Leerink Partnrs cut their Q2 2026 earnings per share (EPS) estimates for McKesson in a note issued to investors on Thursday, August 7th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $8.32 for the quarter, down from their prior forecast of $8.41. The consensus estimate for McKesson's current full-year earnings is $32.77 per share. Leerink Partnrs also issued estimates for McKesson's Q4 2026 earnings at $11.21 EPS.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $8.26 earnings per share for the quarter, missing analysts' consensus estimates of $8.33 by ($0.07). McKesson had a net margin of 0.84% and a negative return on equity of 196.66%. The firm had revenue of $97.83 billion for the quarter, compared to analysts' expectations of $95.93 billion. During the same quarter in the previous year, the business earned $7.88 EPS. The company's revenue for the quarter was up 23.4% on a year-over-year basis.

MCK has been the subject of a number of other research reports. Morgan Stanley reaffirmed an "overweight" rating and issued a $810.00 price target (up previously from $770.00) on shares of McKesson in a report on Wednesday, July 16th. UBS Group increased their price target on shares of McKesson from $708.00 to $805.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Wall Street Zen downgraded shares of McKesson from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 13th. Bank of America increased their price target on shares of McKesson from $755.00 to $800.00 and gave the company a "buy" rating in a report on Friday, May 9th. Finally, Evercore ISI raised their price objective on shares of McKesson from $760.00 to $800.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, McKesson currently has a consensus rating of "Moderate Buy" and a consensus target price of $718.73.

McKesson Trading Up 0.6%

Shares of NYSE:MCK opened at $667.14 on Monday. McKesson has a 12 month low of $464.42 and a 12 month high of $737.89. The company has a 50-day moving average price of $714.12 and a 200 day moving average price of $680.33. The company has a market cap of $82.98 billion, a price-to-earnings ratio of 26.60, a PEG ratio of 1.32 and a beta of 0.50.

McKesson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 1st. Stockholders of record on Tuesday, September 2nd will be paid a dividend of $0.82 per share. This is a boost from McKesson's previous quarterly dividend of $0.71. This represents a $3.28 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, September 2nd. McKesson's payout ratio is presently 11.32%.

Insider Activity

In other news, CFO Britt J. Vitalone sold 1,878 shares of McKesson stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $717.91, for a total transaction of $1,348,234.98. Following the completion of the sale, the chief financial officer owned 14,028 shares of the company's stock, valued at approximately $10,070,841.48. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Napoleon B. Rutledge, Jr. sold 543 shares of McKesson stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $726.51, for a total transaction of $394,494.93. Following the transaction, the chief accounting officer directly owned 1,972 shares in the company, valued at approximately $1,432,677.72. The trade was a 21.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 52,488 shares of company stock valued at $37,242,862. Insiders own 0.08% of the company's stock.

Hedge Funds Weigh In On McKesson

Several institutional investors have recently bought and sold shares of MCK. Brighton Jones LLC increased its holdings in McKesson by 46.3% during the fourth quarter. Brighton Jones LLC now owns 2,523 shares of the company's stock valued at $1,438,000 after buying an additional 798 shares during the period. Crux Wealth Advisors purchased a new position in McKesson during the fourth quarter valued at approximately $291,000. Sagespring Wealth Partners LLC purchased a new position in McKesson during the fourth quarter valued at approximately $529,000. Advisors Capital Management LLC increased its holdings in McKesson by 2.6% during the fourth quarter. Advisors Capital Management LLC now owns 45,959 shares of the company's stock valued at $26,193,000 after buying an additional 1,157 shares during the period. Finally, SageView Advisory Group LLC grew its holdings in McKesson by 7.9% in the fourth quarter. SageView Advisory Group LLC now owns 1,028 shares of the company's stock worth $586,000 after purchasing an additional 75 shares during the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.